Company profile: Mammoth Biosciences
1.1 - Company Overview
Company description
- Provider of CRISPR-based diagnostics, therapeutics, and protein discovery solutions. The DETECTR Platform delivers instrument-free nucleic acid detection for disease; therapeutics offer precision genome editing using novel CRISPR-Cas enzymes; and a proprietary platform discovers new CRISPR systems and Cas proteins for applications in research, agriculture, and biodefense.
Products and services
- DETECTR® Platform: Engineers a CRISPR-based diagnostic system that detects specific nucleic acids indicative of disease and delivers instrument-free results
- Protein Discovery: Produces a proprietary discovery platform that identifies novel CRISPR systems and Cas proteins, expanding CRISPR application scope across research, agriculture, biodefense, and disease detection
- Therapeutics: Architects CRISPR-based precision editing for therapeutic applications, leveraging novel CRISPR-Cas enzymes to enable targeted genome editing
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Mammoth Biosciences
Gentris
HQ: United States
Website
- Description: Provider of global pharmacogenomic testing and biorepository services, helping pharmaceutical companies and clinical research organizations integrate pharmacogenomics into drug development to deliver safer, more effective compounds to market more quickly.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Gentris company profile →
Arrakis Therapeutics
HQ: United States
Website
- Description: Provider of RNA-targeted drug discovery tools and small-molecule therapeutics, including the rSM Toolkit to identify RNA substructures, Direct Modulators that bind RNA, Targeted RNA Degraders, and Covalent Modifiers that block translation. Maintains pipeline programs for cancer, cardiovascular conditions, neurodegeneration, and rare diseases, including an rSM program for DM1.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Arrakis Therapeutics company profile →
HomeDNA
HQ: United States
Website
- Description: Provider of a home paternity test kit; a pharmaceutical firm.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full HomeDNA company profile →
TriLink BioTechnologies
HQ: United States
Website
- Description: Provider of custom oligonucleotides, modified nucleotides, long RNA and mRNA for the diagnostic, therapeutic and OEM markets, offering mRNA synthesis services and GMP mRNA manufacturing, CleanCap capping solutions, custom NTPs, specialty oligo synthesis, and in-house analytical method development and testing; also supplies CleanAmp PCR products and phosphoramidites.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full TriLink BioTechnologies company profile →
MyoNexus Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage gene therapies for limb-girdle muscular dystrophy (LGMD) types 2D, 2B, 2E, 2L, and 2C based on research at Nationwide Children’s Hospital; RNA exon-skipping technologies for rare diseases, particularly Duchenne muscular dystrophy, using PMO with next-generation PPMO in development; gene editing research; and precision genetic medicine platforms for Charcot-Marie-Tooth disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MyoNexus Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Mammoth Biosciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Mammoth Biosciences
2.2 - Growth funds investing in similar companies to Mammoth Biosciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Mammoth Biosciences
4.2 - Public trading comparable groups for Mammoth Biosciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →